Ki-67 is a powerful tool for grading neuroendocrine tumors among Egyptian patients: a 10-year experience

Salama, Asmaa; Badawy, Omnia M.; Mokhtar, Nadia

doi:10.1007/s00432-014-1603-9

Cited by 10 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our country, Ki-67 was found to be somewhat higher in male patients; however, no significant correlation was found between sex and Ki-67. In a study carried out on a total of 112 patients, similar to our study, Salama et al [18] could not find a significant correlation between sex of the patients and the tumor grade.…”

Section: Discussionsupporting

confidence: 81%

Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors

Özaslan¹,

Demir²,

Karaca³

et al. 2016

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 81%

Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors

Özaslan¹,

Demir²,

Karaca³

et al. 2016

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

show abstract

“…Nadler et al [13] suggest that Ki-67 is a proliferative marker for NETs that is highly reproducible when used to grade tumors according to the ENETS and WHO staging systems. The study by Salama et al [14] also supports this finding. Unfortunately, due to small sample size, in our study, histologic grade is not associated with survival in patients with surgical resection.…”

Section: Sexmentioning

confidence: 59%

A 13-year experience with gastric neuroendocrine tumors: A single institute study

Mun

Chin

Jun

2018

Korean J Clin Oncol

View full text Add to dashboard Cite

Purpose: Gastric neuroendocrine tumors (GNETs) are relatively uncommon. Although they frequently follow indolent clinical courses, GNETs have the potential for metastasis. The aim of this study was to analyze the clinicopathological characteristics of GNETs and explore the prognostic factors associated with overall survival of patients with GNETs. Methods: All patients who underwent resection of GNETs from 2003 to 2016 at St. Vincent's Hospital were identified retrospectively. Demographic data, tumor characteristics, and survival results were evaluated. Results: Of the 32 patients with GNETs, 10 patients (31.3%) had an endoscopic resection and 22 (68.7%) had a surgical resection. In terms of the European Neuroendocrine Tumor Society (ENETS) tumor-node-metastasis (TNM) staging systems, three (9.4%), seven (21.9%), five (15.6%), 13 (40.6%), and four patients (12.5%) were classified as stages 0, I, II, III, and IV, respectively. Overall survival differed significantly according to disease stage. Patients with positive symptoms, larger tumor size, and advanced stage had lower survival rates than those with other types. Conclusion: ENETS TNM stage is a reliable parameter for assessment of the prognosis of patients with GNETs. Clinical symptoms, tumor size, and TNM stage are associated with survival of patients with GNETs.

show abstract

“…Yao et al [ 7 ] reported that, in multivariate analysis of patients with well-differentiated to moderately-differentiated NETs, disease stage, primary tumor site and histological grade were predictors of OS (p < 0.001). A recent study showed that all G1 and G2 NETs were associated with the N0/N1 stage, while 27% of G3 NETs were associated with the N2/N3 stage and these differences were statistically significant [ 21 ]. In this study of NETLM, 17% were histological grade G1 tumors, 40% had G2 tumors and 43% had G3 tumors.…”

Section: Discussionmentioning

confidence: 99%

Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute

Shin

Hyeon

et al. 2015

Cancer Res Treat

View full text Add to dashboard Cite

PurposeManagement of gastroenteropancreatic (GEP) neuroendocrine tumors with liver metastases (NETLM) presents many clinical challenges. Assessment of the extent of disease and primary tumor site is crucial for management. In this study, we investigated the primary tumor sites and prognostic factors in GEP NETLM among Korean patients.Materials and MethodsWe reviewed the medical records of 72 Korean patients diagnosed with GEP NETLM between January 1999 and May 2013, focusing on their clinical and pathologic characteristics.ResultsThe most frequently encountered primary tumor sites were the pancreas (n=25, 35%), stomach (n=8, 11%), gall bladder (n=4, 6%) and rectum (n=3, 4%). Twenty-five patients (35%) had occult primary tumor. Twelve patients (17%) had histological grade G1 tumors, 30 patients (42%) had G2 tumors, and 30 patients (42%) had G3 tumors. The mean follow-up period after histological confirmation of hepatic metastases was 11.30±2.44 months for G3 tumors, 19.67±4.09 months for G2 tumors, and 30.67±6.51 months for G1 tumors. Multivariate analyses revealed that an unknown primary tumor site (p=0.001) and higher histological grade (p < 0.001) were independent prognostic indicators for shorter overall survival (OS). Most long-term survivors (OS > 24 months) had received antitumor treatment.ConclusionThe primary tumor site most frequently associated with GEP NETLM was the pancreas. Unknown primary tumor and higher histological grade were independent prognostic indicators for shorter OS. Patients identified as being at a risk of shorter OS should be followed up closely.

show abstract

Ki-67 is a powerful tool for grading neuroendocrine tumors among Egyptian patients: a 10-year experience

Abstract: Ki-67 is a reliable and reproducible marker for grading of NETs and more superior than mitotic rate.

Cited by 10 publications

References 16 publications

Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors

Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors

A 13-year experience with gastric neuroendocrine tumors: A single institute study

Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute

Contact Info

Product

Resources

About